SEC Form 4 · accession 0001209191-18-039523
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeffrey M Leiden
Officer — CEO & President · Director
Period of report
Jun 22, 2018
Accepted (ET)
Jun 26, 2018 · 5:18 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 22, 2018 | M | 106,500 | $83.36 | A | 297,260 | D | |
| Common Stock | Jun 22, 2018 | S | 140,211 | $160.00 | D | 157,049 | D | |
| Common Stock | holding | — | — | — | 440 | I | 401(k) |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $83.36 | Jun 22, 2018 | M | 106,500 | D | — | Jul 29, 2023 | Common Stock | 106,500 | 0 | D |
Explanation of responses
- F1Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1.
- F2Fully vested.